|Bid||183.00 x 100|
|Ask||189.20 x 300|
|Day's Range||187.60 - 189.72|
|52 Week Range||150.38 - 191.10|
|PE Ratio (TTM)||17.10|
|Earnings Date||Feb 1, 2018|
|Forward Dividend & Yield||5.28 (2.79%)|
|1y Target Est||192.59|
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab).
THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS® (carfilzomib).
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Results Support Early ...
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal.
How Is Amgen Positioned for 2018? In January 2018, the FDA approved Amgen’s (AMGN) supplemental Biologics License Application (or sBLA) for Xgeva. Xgeva is used for the prevention of skeletal-related events in individuals with bone metastasis from solid tumors.